Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Cytokinetics Inc., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Cytokinetics Inc. debt to capital ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Cytokinetics Inc. debt to capital ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Cytokinetics Inc. debt to assets ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Cytokinetics Inc. debt to assets ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Cytokinetics Inc. interest coverage ratio deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 not reaching Q1 2023 level. |
Debt to Equity
Cytokinetics Inc., debt to equity calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of long-term debt | —) | —) | —) | —) | —) | —) | —) | —) | 16,875) | 11,250) | 5,625) | —) | —) | —) | —) | —) | —) | —) | 6,212) | 2,607) | 3,778) | 1,703) | —) | |||||||
| Term loan, net, excluding current portion | 60,885) | 62,492) | 64,110) | 63,810) | 63,544) | 62,344) | 61,165) | 47,367) | 30,203) | 35,538) | 40,874) | 46,209) | 45,920) | 45,631) | 45,340) | 45,052) | 44,762) | 44,473) | 36,382) | 39,806) | 38,127) | 30,662) | 31,954) | |||||||
| Convertible notes, net | 548,134) | 547,288) | 546,513) | 545,808) | 544,986) | 134,674) | 134,511) | 95,471) | 93,885) | 92,348) | 90,889) | 89,504) | 88,102) | 86,743) | 85,455) | 84,205) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt | 609,019) | 609,780) | 610,623) | 609,618) | 608,530) | 197,018) | 195,676) | 142,838) | 140,963) | 139,136) | 137,388) | 135,713) | 134,022) | 132,374) | 130,795) | 129,257) | 44,762) | 44,473) | 42,594) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Stockholders’ equity (deficit) | (438,801) | (333,115) | (229,020) | (107,900) | (15,977) | 111,414) | 116,261) | 243,863) | 249,020) | 16,489) | 67,846) | 113,383) | 149,605) | (78,080) | (45,711) | (10,937) | (19,869) | (4,896) | 3,372) | 25,934) | 52,069) | 75,170) | 99,599) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity1 | — | — | — | — | — | 1.77 | 1.68 | 0.59 | 0.57 | 8.44 | 2.02 | 1.20 | 0.90 | — | — | — | — | — | 12.63 | 1.64 | 0.80 | 0.43 | 0.32 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 5.02 | 4.74 | 4.68 | 3.67 | 4.35 | 4.98 | 4.51 | 4.98 | 5.96 | 6.53 | 6.24 | 6.58 | 5.70 | 5.94 | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 7.90 | 9.08 | 11.52 | 10.64 | 10.60 | 15.10 | 40.23 | 4.97 | 4.57 | 3.98 | 3.50 | 3.51 | 3.13 | 3.21 | 3.36 | 3.09 | 2.73 | 2.84 | 3.05 | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.30 | 1.18 | 1.19 | 1.27 | 1.20 | 1.29 | 1.42 | 1.24 | 1.20 | 1.23 | 1.23 | 1.34 | 0.90 | 0.95 | 0.94 | 0.91 | 1.41 | 1.56 | 0.40 | — | — | — | — | |||||||
| Danaher Corp. | 0.42 | 0.38 | 0.39 | 0.39 | 0.41 | 0.43 | 0.47 | 0.49 | 0.54 | 0.48 | 0.50 | 0.53 | 0.57 | 0.62 | 0.84 | 0.72 | 0.54 | 0.32 | 0.30 | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.80 | 1.70 | 1.69 | 1.52 | 1.58 | 1.97 | 1.77 | 1.88 | 2.20 | 2.56 | 2.35 | 2.94 | 3.51 | 3.99 | 5.60 | 5.88 | 4.50 | 5.68 | 6.44 | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.12 | 1.19 | 1.20 | 1.19 | 1.20 | 1.30 | 1.32 | 1.27 | 1.29 | 1.53 | 1.59 | 1.73 | 1.68 | 1.34 | 1.09 | 1.09 | 1.19 | 1.15 | 1.21 | — | — | — | — | |||||||
| Johnson & Johnson | 0.42 | 0.61 | 0.75 | 0.52 | 0.43 | 0.43 | 0.44 | 0.46 | 0.48 | 0.48 | 0.51 | 0.56 | 0.59 | 0.48 | 0.45 | 0.47 | 0.50 | 0.48 | 0.50 | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.85 | 0.95 | 0.66 | 0.67 | 0.68 | 0.73 | 0.78 | 0.87 | 0.74 | 0.80 | 1.16 | 1.26 | 0.98 | 1.12 | 1.07 | 1.02 | 0.97 | 0.96 | 0.94 | — | — | — | — | |||||||
| Moderna Inc. | 0.04 | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — | — | |||||||
| Pfizer Inc. | 0.66 | 0.66 | 0.36 | 0.37 | 0.40 | 0.46 | 0.44 | 0.50 | 0.53 | 0.56 | 0.58 | 0.63 | 0.97 | 0.99 | 0.80 | 0.83 | 0.81 | 0.78 | 0.77 | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.14 | 0.16 | 0.18 | 0.23 | 0.24 | 0.27 | 0.24 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.78 | 0.78 | 0.83 | 0.78 | 0.67 | 0.72 | 0.81 | 0.85 | 0.56 | 0.51 | 0.53 | 0.63 | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= 609,019 ÷ -438,801 = —
2 Click competitor name to see calculations.
Debt to Equity (including Operating Lease Liability)
Cytokinetics Inc., debt to equity (including operating lease liability) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of long-term debt | —) | —) | —) | —) | —) | —) | —) | —) | 16,875) | 11,250) | 5,625) | —) | —) | —) | —) | —) | —) | —) | 6,212) | 2,607) | 3,778) | 1,703) | —) | |||||||
| Term loan, net, excluding current portion | 60,885) | 62,492) | 64,110) | 63,810) | 63,544) | 62,344) | 61,165) | 47,367) | 30,203) | 35,538) | 40,874) | 46,209) | 45,920) | 45,631) | 45,340) | 45,052) | 44,762) | 44,473) | 36,382) | 39,806) | 38,127) | 30,662) | 31,954) | |||||||
| Convertible notes, net | 548,134) | 547,288) | 546,513) | 545,808) | 544,986) | 134,674) | 134,511) | 95,471) | 93,885) | 92,348) | 90,889) | 89,504) | 88,102) | 86,743) | 85,455) | 84,205) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt | 609,019) | 609,780) | 610,623) | 609,618) | 608,530) | 197,018) | 195,676) | 142,838) | 140,963) | 139,136) | 137,388) | 135,713) | 134,022) | 132,374) | 130,795) | 129,257) | 44,762) | 44,473) | 42,594) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Short-term operating lease liabilities | 17,236) | 15,701) | 14,263) | 12,829) | 16,056) | 14,303) | 14,490) | 14,863) | 13,586) | 12,190) | 5,295) | 2,785) | 3,943) | 5,075) | 5,030) | 4,616) | 4,577) | 4,538) | 4,499) | —) | —) | —) | —) | |||||||
| Long-term operating lease liabilities | 122,216) | 123,829) | 125,341) | 126,895) | 114,405) | 112,732) | 112,023) | 112,229) | 106,313) | 95,713) | 85,633) | 440) | 517) | 591) | 1,774) | 2,195) | 3,257) | 4,294) | 5,272) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 748,471) | 749,310) | 750,227) | 749,342) | 738,991) | 324,053) | 322,189) | 269,930) | 260,862) | 247,039) | 228,316) | 138,938) | 138,482) | 138,040) | 137,599) | 136,068) | 52,596) | 53,305) | 52,365) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Stockholders’ equity (deficit) | (438,801) | (333,115) | (229,020) | (107,900) | (15,977) | 111,414) | 116,261) | 243,863) | 249,020) | 16,489) | 67,846) | 113,383) | 149,605) | (78,080) | (45,711) | (10,937) | (19,869) | (4,896) | 3,372) | 25,934) | 52,069) | 75,170) | 99,599) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity (including operating lease liability)1 | — | — | — | — | — | 2.91 | 2.77 | 1.11 | 1.05 | 14.98 | 3.37 | 1.23 | 0.93 | — | — | — | — | — | 15.53 | 1.64 | 0.80 | 0.43 | 0.32 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.09 | 0.06 | 0.05 | 0.05 | 0.06 | 0.04 | 0.04 | 0.05 | 0.03 | 0.06 | 0.06 | 0.08 | 0.08 | 0.06 | 0.09 | 0.11 | 0.04 | 0.03 | 0.03 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity (deficit)
= 748,471 ÷ -438,801 = —
2 Click competitor name to see calculations.
Debt to Capital
Cytokinetics Inc., debt to capital calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of long-term debt | —) | —) | —) | —) | —) | —) | —) | —) | 16,875) | 11,250) | 5,625) | —) | —) | —) | —) | —) | —) | —) | 6,212) | 2,607) | 3,778) | 1,703) | —) | |||||||
| Term loan, net, excluding current portion | 60,885) | 62,492) | 64,110) | 63,810) | 63,544) | 62,344) | 61,165) | 47,367) | 30,203) | 35,538) | 40,874) | 46,209) | 45,920) | 45,631) | 45,340) | 45,052) | 44,762) | 44,473) | 36,382) | 39,806) | 38,127) | 30,662) | 31,954) | |||||||
| Convertible notes, net | 548,134) | 547,288) | 546,513) | 545,808) | 544,986) | 134,674) | 134,511) | 95,471) | 93,885) | 92,348) | 90,889) | 89,504) | 88,102) | 86,743) | 85,455) | 84,205) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt | 609,019) | 609,780) | 610,623) | 609,618) | 608,530) | 197,018) | 195,676) | 142,838) | 140,963) | 139,136) | 137,388) | 135,713) | 134,022) | 132,374) | 130,795) | 129,257) | 44,762) | 44,473) | 42,594) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Stockholders’ equity (deficit) | (438,801) | (333,115) | (229,020) | (107,900) | (15,977) | 111,414) | 116,261) | 243,863) | 249,020) | 16,489) | 67,846) | 113,383) | 149,605) | (78,080) | (45,711) | (10,937) | (19,869) | (4,896) | 3,372) | 25,934) | 52,069) | 75,170) | 99,599) | |||||||
| Total capital | 170,218) | 276,665) | 381,603) | 501,718) | 592,553) | 308,432) | 311,937) | 386,701) | 389,983) | 155,625) | 205,234) | 249,096) | 283,627) | 54,294) | 85,084) | 118,320) | 24,893) | 39,577) | 45,966) | 68,347) | 93,974) | 107,535) | 131,553) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital1 | 3.58 | 2.20 | 1.60 | 1.22 | 1.03 | 0.64 | 0.63 | 0.37 | 0.36 | 0.89 | 0.67 | 0.54 | 0.47 | 2.44 | 1.54 | 1.09 | 1.80 | 1.12 | 0.93 | 0.62 | 0.45 | 0.30 | 0.24 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.83 | 0.83 | 0.82 | 0.79 | 0.81 | 0.83 | 0.82 | 0.83 | 0.86 | 0.87 | 0.86 | 0.87 | 0.85 | 0.86 | 1.12 | 1.14 | 1.27 | 1.30 | 1.27 | — | — | — | — | |||||||
| Amgen Inc. | 0.89 | 0.90 | 0.92 | 0.91 | 0.91 | 0.94 | 0.98 | 0.83 | 0.82 | 0.80 | 0.78 | 0.78 | 0.76 | 0.76 | 0.77 | 0.76 | 0.73 | 0.74 | 0.75 | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.56 | 0.54 | 0.54 | 0.56 | 0.54 | 0.56 | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.47 | 0.49 | 0.48 | 0.48 | 0.59 | 0.61 | 0.28 | — | — | — | — | |||||||
| Danaher Corp. | 0.30 | 0.28 | 0.28 | 0.28 | 0.29 | 0.30 | 0.32 | 0.33 | 0.35 | 0.32 | 0.33 | 0.35 | 0.37 | 0.38 | 0.46 | 0.42 | 0.35 | 0.24 | 0.23 | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.64 | 0.63 | 0.63 | 0.60 | 0.61 | 0.66 | 0.64 | 0.65 | 0.69 | 0.72 | 0.70 | 0.75 | 0.78 | 0.80 | 0.85 | 0.85 | 0.82 | 0.85 | 0.87 | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.53 | 0.54 | 0.55 | 0.54 | 0.54 | 0.56 | 0.57 | 0.56 | 0.56 | 0.60 | 0.61 | 0.63 | 0.63 | 0.57 | 0.52 | 0.52 | 0.54 | 0.54 | 0.55 | — | — | — | — | |||||||
| Johnson & Johnson | 0.30 | 0.38 | 0.43 | 0.34 | 0.30 | 0.30 | 0.31 | 0.31 | 0.33 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 | 0.31 | 0.32 | 0.33 | 0.33 | 0.33 | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.46 | 0.49 | 0.40 | 0.40 | 0.41 | 0.42 | 0.44 | 0.46 | 0.42 | 0.44 | 0.54 | 0.56 | 0.50 | 0.53 | 0.52 | 0.50 | 0.49 | 0.49 | 0.48 | — | — | — | — | |||||||
| Moderna Inc. | 0.04 | 0.05 | 0.04 | 0.05 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — | — | |||||||
| Pfizer Inc. | 0.40 | 0.40 | 0.26 | 0.27 | 0.28 | 0.32 | 0.31 | 0.33 | 0.35 | 0.36 | 0.37 | 0.39 | 0.49 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.43 | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.14 | 0.15 | 0.18 | 0.20 | 0.21 | 0.20 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.44 | 0.44 | 0.45 | 0.44 | 0.40 | 0.42 | 0.45 | 0.46 | 0.36 | 0.34 | 0.35 | 0.39 | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 609,019 ÷ 170,218 = 3.58
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Cytokinetics Inc. debt to capital ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Debt to Capital (including Operating Lease Liability)
Cytokinetics Inc., debt to capital (including operating lease liability) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of long-term debt | —) | —) | —) | —) | —) | —) | —) | —) | 16,875) | 11,250) | 5,625) | —) | —) | —) | —) | —) | —) | —) | 6,212) | 2,607) | 3,778) | 1,703) | —) | |||||||
| Term loan, net, excluding current portion | 60,885) | 62,492) | 64,110) | 63,810) | 63,544) | 62,344) | 61,165) | 47,367) | 30,203) | 35,538) | 40,874) | 46,209) | 45,920) | 45,631) | 45,340) | 45,052) | 44,762) | 44,473) | 36,382) | 39,806) | 38,127) | 30,662) | 31,954) | |||||||
| Convertible notes, net | 548,134) | 547,288) | 546,513) | 545,808) | 544,986) | 134,674) | 134,511) | 95,471) | 93,885) | 92,348) | 90,889) | 89,504) | 88,102) | 86,743) | 85,455) | 84,205) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt | 609,019) | 609,780) | 610,623) | 609,618) | 608,530) | 197,018) | 195,676) | 142,838) | 140,963) | 139,136) | 137,388) | 135,713) | 134,022) | 132,374) | 130,795) | 129,257) | 44,762) | 44,473) | 42,594) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Short-term operating lease liabilities | 17,236) | 15,701) | 14,263) | 12,829) | 16,056) | 14,303) | 14,490) | 14,863) | 13,586) | 12,190) | 5,295) | 2,785) | 3,943) | 5,075) | 5,030) | 4,616) | 4,577) | 4,538) | 4,499) | —) | —) | —) | —) | |||||||
| Long-term operating lease liabilities | 122,216) | 123,829) | 125,341) | 126,895) | 114,405) | 112,732) | 112,023) | 112,229) | 106,313) | 95,713) | 85,633) | 440) | 517) | 591) | 1,774) | 2,195) | 3,257) | 4,294) | 5,272) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 748,471) | 749,310) | 750,227) | 749,342) | 738,991) | 324,053) | 322,189) | 269,930) | 260,862) | 247,039) | 228,316) | 138,938) | 138,482) | 138,040) | 137,599) | 136,068) | 52,596) | 53,305) | 52,365) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Stockholders’ equity (deficit) | (438,801) | (333,115) | (229,020) | (107,900) | (15,977) | 111,414) | 116,261) | 243,863) | 249,020) | 16,489) | 67,846) | 113,383) | 149,605) | (78,080) | (45,711) | (10,937) | (19,869) | (4,896) | 3,372) | 25,934) | 52,069) | 75,170) | 99,599) | |||||||
| Total capital (including operating lease liability) | 309,670) | 416,195) | 521,207) | 641,442) | 723,014) | 435,467) | 438,450) | 513,793) | 509,882) | 263,528) | 296,162) | 252,321) | 288,087) | 59,960) | 91,888) | 125,131) | 32,727) | 48,409) | 55,737) | 68,347) | 93,974) | 107,535) | 131,553) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital (including operating lease liability)1 | 2.42 | 1.80 | 1.44 | 1.17 | 1.02 | 0.74 | 0.73 | 0.53 | 0.51 | 0.94 | 0.77 | 0.55 | 0.48 | 2.30 | 1.50 | 1.09 | 1.61 | 1.10 | 0.94 | 0.62 | 0.45 | 0.30 | 0.24 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.09 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.05 | 0.03 | 0.06 | 0.06 | 0.07 | 0.07 | 0.05 | 0.08 | 0.10 | 0.04 | 0.03 | 0.03 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 748,471 ÷ 309,670 = 2.42
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Cytokinetics Inc. debt to capital ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Debt to Assets
Cytokinetics Inc., debt to assets calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of long-term debt | —) | —) | —) | —) | —) | —) | —) | —) | 16,875) | 11,250) | 5,625) | —) | —) | —) | —) | —) | —) | —) | 6,212) | 2,607) | 3,778) | 1,703) | —) | |||||||
| Term loan, net, excluding current portion | 60,885) | 62,492) | 64,110) | 63,810) | 63,544) | 62,344) | 61,165) | 47,367) | 30,203) | 35,538) | 40,874) | 46,209) | 45,920) | 45,631) | 45,340) | 45,052) | 44,762) | 44,473) | 36,382) | 39,806) | 38,127) | 30,662) | 31,954) | |||||||
| Convertible notes, net | 548,134) | 547,288) | 546,513) | 545,808) | 544,986) | 134,674) | 134,511) | 95,471) | 93,885) | 92,348) | 90,889) | 89,504) | 88,102) | 86,743) | 85,455) | 84,205) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt | 609,019) | 609,780) | 610,623) | 609,618) | 608,530) | 197,018) | 195,676) | 142,838) | 140,963) | 139,136) | 137,388) | 135,713) | 134,022) | 132,374) | 130,795) | 129,257) | 44,762) | 44,473) | 42,594) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Total assets | 740,614) | 779,899) | 889,815) | 1,014,775) | 1,075,961) | 771,717) | 856,253) | 841,319) | 827,539) | 564,302) | 577,062) | 533,803) | 474,112) | 232,495) | 256,582) | 289,814) | 187,393) | 198,218) | 198,611) | 211,178) | 230,279) | 247,239) | 279,926) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets1 | 0.82 | 0.78 | 0.69 | 0.60 | 0.57 | 0.26 | 0.23 | 0.17 | 0.17 | 0.25 | 0.24 | 0.25 | 0.28 | 0.57 | 0.51 | 0.45 | 0.24 | 0.22 | 0.21 | 0.20 | 0.18 | 0.13 | 0.11 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.45 | 0.45 | 0.46 | 0.46 | 0.49 | 0.51 | 0.51 | 0.52 | 0.54 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.74 | 0.75 | 0.65 | 0.65 | 0.65 | — | — | — | — | |||||||
| Amgen Inc. | 0.67 | 0.68 | 0.69 | 0.60 | 0.61 | 0.62 | 0.62 | 0.54 | 0.58 | 0.55 | 0.52 | 0.52 | 0.53 | 0.53 | 0.52 | 0.50 | 0.50 | 0.52 | 0.52 | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.41 | 0.40 | 0.40 | 0.41 | 0.40 | 0.42 | 0.44 | 0.41 | 0.40 | 0.41 | 0.41 | 0.43 | 0.36 | 0.36 | 0.36 | 0.36 | 0.43 | 0.45 | 0.17 | — | — | — | — | |||||||
| Danaher Corp. | 0.25 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.29 | 0.26 | 0.27 | 0.28 | 0.30 | 0.31 | 0.38 | 0.35 | 0.29 | 0.19 | 0.18 | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.35 | 0.34 | 0.36 | 0.33 | 0.33 | 0.36 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.36 | 0.39 | 0.39 | 0.42 | 0.39 | 0.40 | 0.41 | 0.42 | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.40 | 0.40 | 0.41 | 0.40 | 0.40 | 0.42 | 0.42 | 0.39 | 0.41 | 0.44 | 0.45 | 0.46 | 0.48 | 0.43 | 0.40 | 0.40 | 0.42 | 0.41 | 0.42 | — | — | — | — | |||||||
| Johnson & Johnson | 0.18 | 0.24 | 0.27 | 0.21 | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.22 | 0.19 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.33 | 0.35 | 0.29 | 0.28 | 0.28 | 0.30 | 0.30 | 0.31 | 0.28 | 0.29 | 0.34 | 0.35 | 0.32 | 0.34 | 0.33 | 0.31 | 0.31 | 0.32 | 0.31 | — | — | — | — | |||||||
| Moderna Inc. | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | — | — | — | — | |||||||
| Pfizer Inc. | 0.30 | 0.30 | 0.18 | 0.18 | 0.19 | 0.21 | 0.20 | 0.21 | 0.22 | 0.23 | 0.25 | 0.26 | 0.35 | 0.36 | 0.31 | 0.31 | 0.31 | 0.30 | 0.29 | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.13 | 0.15 | 0.16 | 0.17 | 0.15 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.36 | 0.36 | 0.37 | 0.35 | 0.32 | 0.33 | 0.36 | 0.37 | 0.29 | 0.28 | 0.28 | 0.31 | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 609,019 ÷ 740,614 = 0.82
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Cytokinetics Inc. debt to assets ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Debt to Assets (including Operating Lease Liability)
Cytokinetics Inc., debt to assets (including operating lease liability) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of long-term debt | —) | —) | —) | —) | —) | —) | —) | —) | 16,875) | 11,250) | 5,625) | —) | —) | —) | —) | —) | —) | —) | 6,212) | 2,607) | 3,778) | 1,703) | —) | |||||||
| Term loan, net, excluding current portion | 60,885) | 62,492) | 64,110) | 63,810) | 63,544) | 62,344) | 61,165) | 47,367) | 30,203) | 35,538) | 40,874) | 46,209) | 45,920) | 45,631) | 45,340) | 45,052) | 44,762) | 44,473) | 36,382) | 39,806) | 38,127) | 30,662) | 31,954) | |||||||
| Convertible notes, net | 548,134) | 547,288) | 546,513) | 545,808) | 544,986) | 134,674) | 134,511) | 95,471) | 93,885) | 92,348) | 90,889) | 89,504) | 88,102) | 86,743) | 85,455) | 84,205) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt | 609,019) | 609,780) | 610,623) | 609,618) | 608,530) | 197,018) | 195,676) | 142,838) | 140,963) | 139,136) | 137,388) | 135,713) | 134,022) | 132,374) | 130,795) | 129,257) | 44,762) | 44,473) | 42,594) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Short-term operating lease liabilities | 17,236) | 15,701) | 14,263) | 12,829) | 16,056) | 14,303) | 14,490) | 14,863) | 13,586) | 12,190) | 5,295) | 2,785) | 3,943) | 5,075) | 5,030) | 4,616) | 4,577) | 4,538) | 4,499) | —) | —) | —) | —) | |||||||
| Long-term operating lease liabilities | 122,216) | 123,829) | 125,341) | 126,895) | 114,405) | 112,732) | 112,023) | 112,229) | 106,313) | 95,713) | 85,633) | 440) | 517) | 591) | 1,774) | 2,195) | 3,257) | 4,294) | 5,272) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 748,471) | 749,310) | 750,227) | 749,342) | 738,991) | 324,053) | 322,189) | 269,930) | 260,862) | 247,039) | 228,316) | 138,938) | 138,482) | 138,040) | 137,599) | 136,068) | 52,596) | 53,305) | 52,365) | 42,413) | 41,905) | 32,365) | 31,954) | |||||||
| Total assets | 740,614) | 779,899) | 889,815) | 1,014,775) | 1,075,961) | 771,717) | 856,253) | 841,319) | 827,539) | 564,302) | 577,062) | 533,803) | 474,112) | 232,495) | 256,582) | 289,814) | 187,393) | 198,218) | 198,611) | 211,178) | 230,279) | 247,239) | 279,926) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets (including operating lease liability)1 | 1.01 | 0.96 | 0.84 | 0.74 | 0.69 | 0.42 | 0.38 | 0.32 | 0.32 | 0.44 | 0.40 | 0.26 | 0.29 | 0.59 | 0.54 | 0.47 | 0.28 | 0.27 | 0.26 | 0.20 | 0.18 | 0.13 | 0.11 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 | 0.05 | 0.07 | 0.08 | 0.03 | 0.03 | 0.02 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 748,471 ÷ 740,614 = 1.01
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Cytokinetics Inc. debt to assets ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Financial Leverage
Cytokinetics Inc., financial leverage calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Total assets | 740,614) | 779,899) | 889,815) | 1,014,775) | 1,075,961) | 771,717) | 856,253) | 841,319) | 827,539) | 564,302) | 577,062) | 533,803) | 474,112) | 232,495) | 256,582) | 289,814) | 187,393) | 198,218) | 198,611) | 211,178) | 230,279) | 247,239) | 279,926) | |||||||
| Stockholders’ equity (deficit) | (438,801) | (333,115) | (229,020) | (107,900) | (15,977) | 111,414) | 116,261) | 243,863) | 249,020) | 16,489) | 67,846) | 113,383) | 149,605) | (78,080) | (45,711) | (10,937) | (19,869) | (4,896) | 3,372) | 25,934) | 52,069) | 75,170) | 99,599) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Financial leverage1 | — | — | — | — | — | 6.93 | 7.36 | 3.45 | 3.32 | 34.22 | 8.51 | 4.71 | 3.17 | — | — | — | — | — | 58.90 | 8.14 | 4.42 | 3.29 | 2.81 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 11.26 | 10.52 | 10.14 | 8.04 | 8.84 | 9.77 | 8.80 | 9.51 | 10.99 | 11.77 | 10.98 | 11.51 | 9.80 | 10.17 | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 11.83 | 13.31 | 16.59 | 17.79 | 17.44 | 24.51 | 64.62 | 9.13 | 7.91 | 7.25 | 6.70 | 6.69 | 5.90 | 6.10 | 6.50 | 6.17 | 5.45 | 5.50 | 5.91 | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.15 | 2.92 | 2.96 | 3.12 | 3.01 | 3.08 | 3.26 | 3.04 | 2.98 | 3.01 | 2.99 | 3.13 | 2.50 | 2.61 | 2.59 | 2.52 | 3.25 | 3.44 | 2.29 | — | — | — | — | |||||||
| Danaher Corp. | 1.67 | 1.64 | 1.65 | 1.68 | 1.72 | 1.76 | 1.80 | 1.84 | 1.90 | 1.82 | 1.87 | 1.92 | 1.92 | 1.97 | 2.22 | 2.05 | 1.89 | 1.66 | 1.64 | — | — | — | — | |||||||
| Eli Lilly & Co. | 5.16 | 4.95 | 4.75 | 4.65 | 4.71 | 5.51 | 5.03 | 5.44 | 6.21 | 7.42 | 6.79 | 8.27 | 9.10 | 10.25 | 13.35 | 15.07 | 11.20 | 13.91 | 15.32 | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.80 | 2.95 | 2.95 | 2.97 | 2.97 | 3.11 | 3.17 | 3.23 | 3.13 | 3.45 | 3.56 | 3.76 | 3.49 | 3.10 | 2.71 | 2.74 | 2.87 | 2.79 | 2.86 | — | — | — | — | |||||||
| Johnson & Johnson | 2.33 | 2.55 | 2.77 | 2.44 | 2.35 | 2.33 | 2.39 | 2.46 | 2.55 | 2.54 | 2.62 | 2.76 | 2.65 | 2.51 | 2.53 | 2.65 | 2.67 | 2.55 | 2.54 | — | — | — | — | |||||||
| Merck & Co. Inc. | 2.59 | 2.70 | 2.30 | 2.37 | 2.41 | 2.48 | 2.61 | 2.77 | 2.61 | 2.72 | 3.37 | 3.62 | 3.08 | 3.28 | 3.24 | 3.26 | 3.10 | 3.04 | 2.99 | — | — | — | — | |||||||
| Moderna Inc. | 1.45 | 1.29 | 1.28 | 1.35 | 1.45 | 1.45 | 1.62 | 1.74 | 2.07 | 2.41 | 3.31 | 2.86 | 1.69 | 1.18 | 1.26 | 1.35 | 1.27 | 1.26 | 1.25 | — | — | — | — | |||||||
| Pfizer Inc. | 2.22 | 2.22 | 1.94 | 2.06 | 2.10 | 2.24 | 2.23 | 2.35 | 2.37 | 2.43 | 2.31 | 2.44 | 2.74 | 2.77 | 2.56 | 2.65 | 2.62 | 2.62 | 2.64 | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.29 | 1.28 | 1.28 | 1.29 | 1.29 | 1.32 | 1.32 | 1.36 | 1.37 | 1.42 | 1.48 | 1.56 | 1.59 | 1.59 | 1.30 | 1.34 | 1.33 | 1.35 | 1.36 | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 2.14 | 2.15 | 2.24 | 2.21 | 2.08 | 2.14 | 2.26 | 2.33 | 1.90 | 1.84 | 1.88 | 2.00 | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= 740,614 ÷ -438,801 = —
2 Click competitor name to see calculations.
Interest Coverage
Cytokinetics Inc., interest coverage calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Net loss | (129,422) | (128,637) | (131,289) | (137,380) | (142,310) | (19,820) | (89,445) | (30,570) | (76,086) | (61,554) | (47,104) | (43,930) | (3,175) | (40,780) | (39,405) | (30,640) | (29,573) | (32,113) | (29,366) | (26,468) | (22,017) | (27,523) | (30,281) | |||||||
| Add: Income tax expense | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Add: Interest expense | 7,136) | 7,045) | 6,961) | 7,057) | 6,804) | 2,807) | 2,746) | 4,218) | 4,161) | 4,073) | 3,988) | 4,018) | 3,976) | 3,892) | 4,077) | 2,731) | 1,345) | 1,377) | 1,170) | 1,169) | 867) | 898) | 863) | |||||||
| Earnings before interest and tax (EBIT) | (122,286) | (121,592) | (124,328) | (130,323) | (135,506) | (17,013) | (86,699) | (26,352) | (71,925) | (57,481) | (43,116) | (39,912) | 801) | (36,888) | (35,328) | (27,909) | (28,228) | (30,736) | (28,196) | (25,299) | (21,150) | (26,625) | (29,418) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Interest coverage1 | -17.68 | -18.36 | -17.23 | -19.03 | -16.02 | -14.50 | -15.95 | -12.10 | -13.08 | -8.70 | -7.50 | -6.97 | -6.77 | -10.66 | -12.82 | -17.37 | -22.22 | -22.99 | -24.68 | -26.99 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 4.54 | 5.43 | 6.51 | 6.22 | 6.83 | 6.97 | 6.40 | 6.60 | 6.46 | 6.48 | 7.64 | 7.44 | 7.62 | 7.62 | 7.85 | 8.09 | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 24.34 | 29.65 | 35.60 | 40.30 | 41.32 | 35.26 | 33.54 | 32.92 | 28.74 | 25.87 | 21.54 | 17.35 | 16.90 | 20.00 | 25.33 | 31.44 | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 8.88 | 9.03 | 8.84 | 7.22 | 5.80 | 6.73 | 6.97 | 9.27 | 10.06 | 7.61 | 2.93 | 2.70 | 2.83 | 0.41 | 5.90 | 6.19 | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 19.09 | 23.89 | 31.49 | 79.71 | 141.63 | 160.27 | 164.15 | 125.46 | 94.27 | 87.06 | 73.87 | 83.07 | 96.82 | 81.36 | 81.56 | 55.49 | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 61.70 | 69.61 | 73.97 | 82.80 | 108.62 | 116.35 | 163.24 | 163.75 | 139.74 | 104.12 | 68.20 | 67.97 | 72.22 | 108.12 | 90.22 | 81.43 | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 5.98 | 6.64 | 8.28 | 11.56 | 13.59 | 15.70 | 16.73 | 17.49 | 19.94 | 19.52 | 17.58 | 14.07 | 10.78 | 7.93 | 7.66 | 7.02 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Interest coverage
= (EBITQ3 2023
+ EBITQ2 2023
+ EBITQ1 2023
+ EBITQ4 2022)
÷ (Interest expenseQ3 2023
+ Interest expenseQ2 2023
+ Interest expenseQ1 2023
+ Interest expenseQ4 2022)
= (-122,286 + -121,592 + -124,328 + -130,323)
÷ (7,136 + 7,045 + 6,961 + 7,057)
= -17.68
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Cytokinetics Inc. interest coverage ratio deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 not reaching Q1 2023 level. |